Endra Life Sciences Inc. · NASDAQ:NDRA
Endra Life Sciences — Investor Presentation (July 2018)
22 slides from Endra Life Sciences's investor presentation, Jul 18, 2018
Slide 1: Bringing New Capabilities to Ultrasound
JULY 2018 Bringing New Capabilities to Ultrasound INVESTOR PRESENTATION NASOAG: NORA
Slide 2: Safe harbor
Safe harbor Certain statements made in this presentation contain forwardiooking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial pos
Slide 3: ENDRA Life Sciences key statistics
ENDRA Life Sciences ENHANCE ULTRASOUND TO SEE HUMAN TISSUE IN WAYS SIMILAR TO CT-MRI... BUT AT 50X LOWER COST? KEY STATISTICS (as of July 10, 2018) Common Stock Price (NASDAG: NDRA) $2.33 Warrant Price (NASDAG: NDRAW)' $0.49 Shares Outstanding 3.9M Market Capitalization $3.1M Management / Director O
Slide 4: The core problem ENDRA is targeting
The core problem ENDRA is targeting GAP BETWEEN IMAGING PERFORMANCE, ACCESS AND SAFETY CT & MRI ENDR CONVENTIONAL ULTRASOUND Many clinical applications Advanced applications Broadly available Ultrasound availability & safety Inexpensive (~$100K) Not broadly available Target $40K ASP Safe (E.g., no r
Slide 5: Thermo Acoustic Enhanced UltraSound (TAEUS)
Thermo Acoustic Enhanced UltraSound (TAEUS”) SHORT RF PULSES DIFFERENTIATE TISSUES IN CONCERT WITH ULTRASOUND S) oe © Traditional ultrasound PF energy is absorbed Sonic waves are TAEUS™ image is and low energy radio by tissues differently detected by ultrasound processed and displayed (RF) waves are
Slide 6: ENDRA's TAEUS platform
ENDRA’s TAEUS™ platform PLANNED APPLICATIONS [eesercrer (Hm | | | Comme Geeemeerreres Qu] (am |G? Venere G2 | Ce re ACCESSORY SOFTWARE #1 SOFTWARE #2 LICENSING SOFTWARE #3-4 Plug into existing Tissue Tissue Build TAEUS into Vascular ultrasound systems Composition Temperature new ultrasounds & Perfus
Slide 7: Opportunity #1: non-alcoholic fatty liver disease (NAFLD)
ENDRA Opportunity #1: non-alcoholic fatty liver disease (NAFLD) ENDRA’S TAEUS WOULD PROVIDE SIGNIFICANT DIAGNOSTIC ADVANTAGES 1.4 BILLION PEOPLE AFFECTED GLOBALLY! * Drivers: obesity, diabetes, Hep-C, drugs * Often asymptomatic, needs to be monitored a * ~30%? of NAFLD cases progress to NASH, then F
Slide 8: Liver disease diagnostic & therapy landscape
Liver disease diagnostic & therapy landscape ENDRA STRATEGICALLY POSITIONED AT FOREFRONT OF GROWING FOCUS ON LIVER DISEASE 1.4B! people ~420M? people ~105M? people Fatty Liver (NAFLD) Inflammation (NASH) Scarring (Fibrosis) © 7) Efalenz _ PHILIPS (36) Heaeare ecHosens Surgical Biopsy Biomarkers Brea
Slide 9: Opportunity #2: energy-based surgery
ENDRA Opportunity #2: energy-based surgery SAFELY AND INEXPENSIVELY MAP THE HEAT SIGNATURE OF TISSUE ABLATION IN REAL-TIME ON ULTRASOUND 5+ MILLION RF ABLATION PROCEDURES ANNUALLY! * Growing 20% CAGR * Driven by aging-related diseases: cancer, pain, cardiology wr CURRENT TOOLS ARE INACCURATE OR IMPR
Slide 10: TAEUS guidance of energy-based surgery
TAEUS guidance of energy-based surgery INEXPENSIVELY AND SAFELY MAP THE HEAT SIGNATURE OF TISSUE ABLATION IN REAL-TIME ON ULTRASOUND Temperature Overlay Ultrasound @ENSRA
Slide 11: Addressable market: ENDRA's accessory & software
Addressable market: ENDRA’s accessory & software LARGE INSTALLED BASE OF DIAGNOSTIC ULTRASOUND SYSTEMS! ULTRASOUND SYSTEMS ENDRA’S ADDRESSABLE MARKET? 2017 estimated global installed Cart-based non-prenatal systems ultrasound systems: 925,000" Out of Scope Mobile and ef 159,000 | Lege 587,000 { 338,
Slide 12: GE Healthcare partnership
ENDRA — GE Healthcare partnership FOCUSED ON EARLY DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE #1 ULTRASOUND MARKET LEADER ENDRA agreement signed April 2016, renewed April 2017 and January 2018 * ENDRA provides 1 year sales exclusivity on TAEUS liver application * GE provides technical advice and
Slide 13: TAEUS technology benefits for key stakeholders
ENDRA TAEUS technology benefits for key stakeholders POTENTIAL 6-MONTH PAYBACK’ UNTIL DEDICATED REIMBURSEMENT SECURED POTENTIAL TAEUS BENEFITS - SHORT TERM CLINICIAN Earlier detection through cost-effective screening e e e Cost-avoidance of CT/MARI: More diagnoses with inexpensive ultrasound e e Pat
Slide 14: TAEUS liver application roadmap
ENDRA TAEUS" liver application roadmap ESTIMATED TIMELINE FOR KEY MILESTONES Y Initiate first human Y GE Partnership Y New patents issued Q1: Full commercial launch: study - CIMTEC renewal: 2 years . TAEUS liver device in Europe First human data Y Kick-off assetlight v New patents 7 Q1: U.S. 510K ap
Slide 15: Asset-light model to bring TAEUS liver to market
Asset-light model to bring TAEUS liver to market PARTNERSHIPS TO HELP EXECUTE ENDRA’S OPERATIONAL PLAN ENDRA leads project management, systems engineering & regulatory submissions 3-4 commercial ENDRA specialists in Europe supporting channel partners & customers TARGET ; CUSTOMERS i DEVELOP & MANUFA
Slide 16: Leadership
Leadership Sam Gambhir, MD Michael Harsh Anthony DiGiandomenico Alex Tokman Chair of Radiology. 36-year GE veteran Co-founder, MDB Capital 10° years GE Healthcare Stenford University Retired CTO, GE Healthcare Former CEO, Microvision Francois Michelon. Michael Thornton David Wells CEO & Chairman cto
Slide 17: Select Clinical Feedback
Select Clinical Feedback reducing g cos! Sam Gambhir, M.D PhD Chair of Radiology, Stanford University ENDRA Board Member “ENDRA’s TAEUS technology could be a game changer for the clinical care cycle of liver (and other) disease - from screening to diagnosis to therapy guidance - especially in market
Slide 18: Life Sciences: investment summary
ENDRA Life Sciences: investment summary Business model: Partnership with Platform technology + capital #1 global ultrasound efficient operating model market leader @ 37 IP assets. $13B addressable Initial focus on Fatty World class team: market for ENDRA's $40K Liver Disease: 1.4B people Stanford, G
Slide 19: Contact
ENDRA CONTACT David Wells Chief Financial Officer (734) 997-0464 investors@endrainc.com www.endrainc.com Contact Us INVESTOR RELATIONS MZ Group Chris Tyson Managing Director (949) 491-8235 NDRA@mzgroup.us
Slide 20: Capitalization Table
Capitalization Table AT JUNE 30, 2018* FULLY COMMON SHARES ISSUED & OUTSTANDING DILUTED Shares Issued in IPO 1,932,000 25.8% Existing Shareholders 1,827,040 24.4% Management & Directors 163,987 2.2% Common Shares Outstanding 3,923,027 52.5% Warrants Issued in IPO 2,086,560 27.9% Warrants Issued for
Slide 21: Ultrasound Technology Evolution
Ultrasound Technology Evolution AHISTORY OF NEW TECHNOLOGIES EXPANDING ULTRASOUND UTILITY AND DRIVING M&A ACTIVITY NEW TECH M&A ADOPTION ENDRA LIFE SCIENCES: 1960 - 2000 Doppler Ultrasound Cardiac imaging 3D imaging Contrast agents Color Doppler a Siemens / Quantum Philips / ATL $800M GE / Vingmed $
Slide 22: Sources and Notes
Sources and Notes PAGE 7 1 The LANCET, Vincent WaiSun Wong, November 2015 2 International Journal of Molecular Sciences, The Natural Course of Non- Alcoholic Fatty Liver Disease, 2016 3 Hepatology, The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
ENDRA Life Sciences — Investor Presentation (July 2018) on 6ix